All In MedTech

Device Trial Radar · NCT07039461

Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion

Last checked: Nov 20, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

4

Actual

Start

Sep 12, 2025

Primary completion

Dec 24, 2025

Study completion Dec 24, 2025

Sponsor

Lead sponsor
Lumenis Be Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Jun 26, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To study the effectiveness and safety of IPL treatment for Chalazion

Conditions

  • Chalazion

Interventions

  • OptiLIGHTDevice

    three IPL or sham treatment in 1 week interval followed by 1 follow-up 4 weeks after the last treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of resolved chalazion 4 weeks after the last treatment in the study group and the control groupTime frame: 4 weeks after the last treatment

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Manhattan Face and Eye clinic

    New York, New York

  • Periman Eye Institute

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.